Pavilion Health Today
Supporting healthcare professionals to deliver the best patient care

MHRA approves enzalutamide to treat men with prostate cancer

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved an additional indication for enzalutamide (Xtandi) for adult men with metastatic hormone-sensitive prostate cancer (mHSPC). 

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved an additional indication for enzalutamide (Xtandi) for adult men with metastatic hormone-sensitive prostate cancer (mHSPC). With this, enzalutamide is now the only oral treatment approved by the MHRA to treat three distinct types of advanced prostate cancer. These are: high risk non-metastatic and metastatic castration-resistant prostate cancer (CRPC), as well as mHSPC. The new treatment has served as welcome news for the sector, as men diagnosed with mHSPC tend to have a poor prognosis, with a median survival of approximately 3-4 years. Men diagnosed with mHSPC have a median survival of approximately 3-4 years

---------------------------

This content is restricted to members of Pavilion Health Today. If you are an existing user, please log in. New users may register for free below.

Existing Users Log In
   
New User Registration
captcha
*Required field

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read more ...

Privacy & Cookies Policy